


11th MILAN CONGRESS ON INNOVATIVE ANTICANCER THERAPY



 Fondazione IRCCS
Istituto Nazionale dei Tumori

Sistema Socio Sanitario

 Regione
Lombardia

WEBINAR CONGRESS

21 January 2021 from 14.50 to 18.40

22 January 2021 from 15.30 to 18.00

FAD

UNDER THE PATRONAGE OF



Fondazione IRCCS
Istituto Nazionale dei Tumori

Sistema Socio Sanitario



Regione
Lombardia

Qui è nata l'Oncologia Italiana

PRESENTATION

The 11th "Milan Congress on Innovative Anticancer Therapy" will present leading international experts in the field of immuno-oncology and cancer cell signaling to investigate the potentials, opportunities and challenges of immunotherapy and targeted therapies. The newest therapeutic approaches will be discussed in the context of the COVID-19 epidemic.

Increased knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, has allowed us to identify and apply more effective biological and immunological anticancer treatments. To date, immuno-biotherapy is a continuously evolving treatment modality and is currently integrated into the treatment algorithms of several different tumor types. Combination treatments based on immune checkpoint inhibitors (ICI) with either targeted therapy, radiotherapy or standard chemotherapy have recently been introduced in clinical practice. Rationale, *pro and contra*, and the identification of a specific subset of patients who could benefit from these approaches will be discussed.

This conference explores topics that will appeal to clinicians, as well as to, basic, translational, and clinical scientists ranging from academia to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, and provide the audience with a broad overview of the most recent achievements in biological and immunological cancer therapy.

Lastly, a wide spectrum of evolving topics in cancer research such as epigenetic drugs and CART cells will be analyzed in view of their introduction in the clinical setting.

FACULTY



ANDREA ANICHINI	(Milan, Italy)
GIOVANNI APOLONE	(Milan, Italy)
FILIPPO DE BRAUD	(Milan, Italy)
MICHELE DEL VECCHIO	(Milan, Italy)
PAOLO DELLABONA	(Milan, Italy)
MASSIMO DI NICOLA	(Milan, Italy)
GIAMPIETRO DOTTI	(Chapel Hill, USA)
SOLDANO FERRONE	(Boston, USA)
LUCA GATTINONI	(Regensburg, Germany)
CHIARA GORRINI	(Toronto, Canada)
AXEL HAUSCHILD	(Kiel, Germany)
JOHN HISCOTT	(Rome, Italy)
MARIA TERESA LANDI	(Bethesda, USA)
ALBERTO MANTOVANI	(Milan, Italy)
MASSIMO MASSAIA	(Cuneo, Italy)
MICHAEL NISHIMURA	(Chicago, USA)
JEFFREY WEBER	(New York, USA)

Thursday, 21 January 2021 · Webinar Congress

- 14.50-14.55 Welcome remarks of Scientific Director - **G. Apolone** (Milan, Italy)
- 14.55-15.00 Introduction - **M. Di Nicola** (Milan, Italy)
- 15.00-15.30 Innate Immunity and Inflammation: from cancer to COVID-19 - **A. Mantovani** (Milan, Italy)

I SESSION: PRECLINICAL EVIDENCES AND NEW TARGETS

Chairmen: **F. de Braud** (Milan, Italy), **S. Ferrone** (Boston, USA)

- 15.30-16.00 Therapeutic implications of redox metabolism in breast cancer - **C. Gorrini** (Toronto, Canada)
- 16.00-16.10 Discussion
- 16.10-16.40 Role of iNKT in adoptive T cell therapy - **P. Dellabona** (Milan, Italy)
- 16.40-16.50 Discussion
- 16.50-17.20 T Cell Receptor Gene Modified T cells for the Immunotherapy of Cancer - **M. Nishimura** (Chicago, USA)
- 17.20-17.30 Discussion
- 17.30-18.00 Mutational signatures and cancer treatment - **M.T. Landi** (Bethesda, USA)
- 18.00-18.10 Discussion

KEYNOTE LECTURE

- 18.10-18.40 Adjuvant setting in Melanoma: it is time to start immunotherapy earlier - **J. Weber** (New York, USA)
Presented by **M. Del Vecchio** (Milan, Italy)

Friday, 22 January 2021 · Webinar Congress

II SESSION: CLINICAL TRANSLATION

Chairmen: **J. Hiscott** (Rome, Italy), **M. Massaia** (Cuneo, Italy)

- 15.30-16.00 Synergistic activity of targeted and immunotherapy: new paradigms - **A. Hauschild** (Kiel, Germany)
16.00-16.10 Discussion
- 16.10-16.40 CART cells in solid tumors: preliminary clinical data - **G. Dotti** (Chapel Hill, USA)
16.40-16.50 Discussion
- 16.50-17.20 Immune monitoring of patients treated with ICI - **A. Anichini** (Milan, Italy)
17.20-17.30 Discussion
- 17.30-18.00 CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
L. Gattinoni (Regensburg, Germany)
18.00-18.10 Discussion
- 18.10-18.25 AWARD FOR THE BEST ABSTRACT
- 18.25-18.30 Conclusions - **M. Del Vecchio** (Milan, Italy)

GENERAL INFORMATION

CONGRESS VENUE

SYNCHRONOUS DISTANCE E-LEARNING

<https://bit.ly/33szgjl>

SCIENTIFIC COMMITTEE

Giovanni Apolone - Milan, Italy

Filippo de Braud - Milan, Italy

Michele Del Vecchio - Milan, Italy

Massimo Di Nicola - Milan, Italy

Gianpietro Dotti - Chapel Hill, USA

Soldano Ferrone - Boston, USA

John Hiscott - Rome, Italy

BEST ABSTRACT AWARD

having as its first author a Researcher
< of 35 years

Send by January 18, 2021

to info@nadirex.com

OFFICIAL LANGUAGE

English

CME PROVIDER NR. 265

ORGANIZING SECRETARIAT



Nadirex International Srl
Via Riviera 39 · 27100 Pavia
Tel. +39.0382.525714/35
Fax +39.0382.525736
gloria.molla@nadirex.com
www.nadirex.com

GENERAL INFORMATIONS

Id ECM: 265-308562

- **Educational goal:** Nr. 2 - Guidelines - Protocols - Procedures
- **Event type:** Remote learning (RL)
- **CME credits:** Nr. 9
- **Participants:** 300
- **RL (Remote Learning) product type:** Live courses on dedicated multimedia platform (Virtual Classroom, Webinar) - Synchronous RL

PARTICIPANT RESOURCES REQUIRED

Email address (for registration), recent and updated web browser, Internet connection, devices to enable use of learning contents (pc, smartphone or tablet) with speakers (or earphones), microphone (only if the course calls for verbal interaction between teachers and participants).

GENERAL INFORMATIONS

ADDRESSES OF THE CONGRESS

The Congress is addressed to the following figures:

- Physician (Disciplines: Hematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)
- Biologist
- Biomedical Laboratory Technician

LEARNING VERIFICATION METHOD

Online multiple-choice questionnaire with double randomization. To earn ECM credits for the event you must:

- attend 90% of the teaching activities
- give correct answers to at least 75% of the questions on the questionnaire (a maximum of five attempts to pass the test are allowed, subject to repetition of content activities for each attempt);
- fill out the RL evaluation form and the quality and learning needs questionnaire

Attention: the questionnaire will be online for only 3 (three) days after the event has concluded.

The Congress is not by direct invitation by the sponsor.

Nadirex International assumes all responsibility for the contents, quality, and ethical correctness of this ECM activity.

For further informations please contact the Organizing Secretariat:
gloria.molla@nadirx.com - tel +39 0382 525736

WITH THE UNRESTRICTED EDUCATIONAL GRANTS OF:

